Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Akebia Therapeutics Inc shares valued at $151,622 were sold by Ostrowski Erik on Jun 30 ’25. At $3.67 per share, Ostrowski Erik sold 41,314 shares. The insider’s holdings dropped to 503,586 shares worth approximately $2.01 million following the completion of this transaction.
Also, Ostrowski Erik purchased 41,314 shares, netting a total of over 151,622 in proceeds.
Before that, Malabre Richard C had sold 15,000 shares from its account. In a trade valued at $60,150, the SVP, Chief Accounting Officer traded Akebia Therapeutics Inc shares for $4.01 each. Upon closing the transaction, the insider’s holdings decreased to 15,000 shares, worth approximately $1.06 million.
Analysts at Leerink Partners started covering the stock with ‘”an Outperform”‘ outlook in a report released in late April. As of April 01, 2025, Jefferies has initiated its “Buy” rating for AKBA.
Analyzing AKBA Stock Performance
On last trading session,, Akebia Therapeutics Inc [NASDAQ: AKBA] rose 7.55% to $3.99. The stock’s lowest price that day was $3.72, but it reached a high of $4.01 in the same session. During the last five days, there has been a surge of approximately 11.76%. Over the course of the year, Akebia Therapeutics Inc shares have jumped approximately 326.42%. Shares of the company reached a 52-week high of $4.08 on 06/09/25 and a 52-week low of $1.52 on 04/10/25.
Support And Resistance Levels for Akebia Therapeutics Inc (AKBA)
According to the 24-hour chart, there is a support level at 3.80, which, if violated, would cause prices to drop to 3.62. In the upper region, resistance lies at 4.09. The next price resistance is at 4.20. RSI (Relative Strength Index) is 70.78 on the 14-day chart, showing overbought technical sentiment.
Is Akebia Therapeutics Inc subject to short interest?
Stocks of Akebia Therapeutics Inc saw a sharp steep in short interest on 2025-06-13 dropping by -1.22 million shares to 18.5 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 19.72 million shares. A decline of -6.62% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.02 of the overall float, the days-to-cover ratio (short ratio) decline to 3.02.
Which companies own the most shares of Akebia Therapeutics Inc (AKBA)?
In terms of Akebia Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 6.5 in the next 12 months, up nearly 75.2% from the previous closing price of $3.71. Analysts anticipate Akebia Therapeutics Inc stock to reach 7 by 2025, with the lowest price target being 6. In spite of this, 4 analysts ranked Akebia Therapeutics Inc stock as Buy at the end of 2025. On August 28, 2023, H.C. Wainwright assigned a price target of “a Buy” to the stock and upgraded coverage with a $3.75.
